#ESMO26 | KEYNOTE-B49

In patients with PD-L1 CPS ≥1, HR+/HER2− mBC previously treated with ET, pembro + chemo was compared with chemo

- PFS: 6.7 vs 6.0 mo (HR 0.74)
- OS: 21.0 vs 22.2 mo (HR 1.04)
- CPS ≥10: PFS HR 0.59

I’m curious to see the subgroup analyses presented at ESMO. However, in the ADC era, this modest PFS benefit without an OS advantage has little clinical relevance to me.

Evaluating immunotherapy in combination with ADCs or after ADC treatment may be more rational in today's treatment landscape.